Live price temporarily unavailable.
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts May 28, 2026, the first target we tracked for TMO.
Thermo Fisher Scientific (TMO) is a Health Care company in the S&P 500. Latest news and coverage below.
Analyst price targets on TMO
Current price targets from 3 firms average $627, median $650, ranging from $580 to $650. Each is tracked to its date and scored the same way a member's call is.
- Morgan Stanley $560 → $650 by Jul 2027 Jul 27, 2026 via GuruFocus · Morgan Stanley's track record
- RBC Capital Markets $568 → $580 by Jul 2027 Jul 24, 2026 via GuruFocus · RBC Capital Markets's track record
- Barclays $568 → $650 by Jul 2027 Jul 24, 2026 via GuruFocus · Barclays's track record
- RBC Capital Markets $487 → $490 by May 2027 May 28, 2026 via Yahoo Finance · RBC Capital Markets's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Thermo Fisher Scientific revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $18.3B | $20.9B | $24.4B | $25.5B | $32.2B | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B |
| Growth (year over year) | +7.7% | +14.5% | +16.4% | +4.9% | +26.1% | +21.7% | +14.5% | −4.6% | +0.1% | +3.9% |
| Gross profit | $10.1B | $11.9B | — | — | — | — | — | — | — | — |
| Gross margin | 55.1% | 57.1% | — | — | — | — | — | — | — | — |
| Operating income | $2.46B | $2.96B | $3.78B | $4.59B | $7.79B | $10.0B | $8.39B | $6.86B | $7.34B | $7.75B |
| Operating margin | 13.5% | 14.2% | 15.5% | 18.0% | 24.2% | 25.6% | 18.7% | 16.0% | 17.1% | 17.4% |
| Net income | $2.02B | $2.23B | $2.94B | $3.70B | $6.38B | $7.72B | $6.95B | $6.00B | $6.33B | $6.70B |
| Net margin | 11.1% | 10.6% | 12.1% | 14.5% | 19.8% | 19.7% | 15.5% | 14.0% | 14.8% | 15.0% |
| EPS (diluted) | $5.09 | $5.59 | $7.24 | $9.17 | $15.96 | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 |
| Balance sheet | ||||||||||
| Cash and equivalents | $786.0M | $1.33B | $2.10B | $2.40B | $10.3B | $4.48B | $8.52B | $8.08B | $4.01B | $9.85B |
| Total assets | $45.9B | $56.7B | $56.2B | $58.4B | $69.1B | $95.1B | $97.2B | $98.7B | $97.3B | $110.3B |
| Total liabilities | $24.4B | $31.3B | $28.6B | $28.7B | $34.5B | $54.3B | $53.1B | $52.0B | $47.8B | $56.9B |
| Long-term debt | $15.4B | $18.9B | $17.7B | $17.1B | $19.1B | $32.3B | $28.9B | $31.3B | $29.1B | $35.9B |
| Shareholders' equity | $21.5B | $25.4B | $27.6B | $29.7B | $34.5B | $40.8B | $44.0B | $46.7B | $49.6B | $53.4B |
| Cash flow | ||||||||||
| Operating cash flow | $3.26B | $4.00B | $4.54B | $4.97B | $8.29B | $9.31B | $9.15B | $8.41B | $8.67B | $7.82B |
| Capital expenditure | $444.0M | $508.0M | $758.0M | $926.0M | $1.47B | $2.52B | $2.24B | $1.48B | $1.40B | $1.52B |
| Free cash flow | $2.81B | $3.50B | $3.79B | $4.05B | $6.82B | $6.79B | $6.91B | $6.93B | $7.27B | $6.29B |
| Dividends paid | $238.0M | $237.0M | $266.0M | $297.0M | $337.0M | $395.0M | $455.0M | $523.0M | $583.0M | $636.0M |
| Share buybacks | $1.25B | $750.0M | $500.0M | $1.50B | $1.50B | $2.00B | $3.00B | $3.00B | $4.00B | $3.00B |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.6B | $11.4B | $10.4B | $10.9B | $11.1B | $12.2B | $11.0B | $12.0B |
| Growth (year over year) | +0.2% | +4.7% | +0.2% | +3.0% | +4.9% | +7.2% | +6.2% | +10.5% |
| Operating income | $1.84B | $2.02B | $1.72B | $1.83B | $1.94B | $2.25B | $1.86B | $2.09B |
| Operating margin | 17.3% | 17.7% | 16.6% | 16.9% | 17.5% | 18.5% | 16.9% | 17.4% |
| Net income | $1.63B | $1.83B | $1.51B | $1.62B | $1.62B | $1.96B | $1.65B | $1.74B |
| Net margin | 15.4% | 16.1% | 14.5% | 14.9% | 14.5% | 16.1% | 15.0% | 14.5% |
| EPS (diluted) | $4.25 | $4.78 | $3.98 | $4.28 | $4.27 | $5.21 | $4.43 | $4.68 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.64B | $4.01B | $4.13B | $4.58B | $1.98B | $9.85B | $3.25B | $4.06B |
| Total assets | $100.4B | $97.3B | $99.0B | $101.2B | $103.0B | $110.3B | $113.3B | $113.2B |
| Total liabilities | $51.4B | $47.8B | $49.7B | $50.8B | $52.0B | $56.9B | $61.3B | $60.5B |
| Long-term debt | $31.2B | $29.1B | $31.4B | $33.0B | $31.9B | $35.9B | $40.1B | $39.2B |
| Shareholders' equity | $49.0B | $49.6B | $49.4B | $50.5B | $51.0B | $53.4B | $51.9B | $52.7B |
| Cash flow | ||||||||
| Operating cash flow | $2.17B | $3.29B | $723.0M | $1.40B | $2.24B | $3.46B | $1.19B | $2.13B |
| Capital expenditure | $272.0M | $480.0M | $362.0M | $294.0M | $404.0M | $465.0M | $376.0M | $450.0M |
| Free cash flow | $1.89B | $2.81B | $361.0M | $1.10B | $1.83B | $2.99B | $816.0M | $1.68B |
| Dividends paid | $150.0M | $149.0M | $149.0M | $162.0M | $163.0M | $162.0M | $162.0M | $175.0M |
| Share buybacks | $0 | $1.00B | $2.00B | $0 | $963.0M | $37.0M | $3.00B | $1.00B |
From Thermo Fisher Scientific's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Source: Wikipedia — Thermo Fisher Scientific
- Headquarters
- Waltham, Massachusetts From SEC filings, Oct 2026
Recent News (20)
-
Is This the Right Time to Add TMO Stock to Your Portfolio? Is This the Right Time to Add TMO Stock to Your Portfolio? TradingView
-
TMO Oct 2026 550.000 call (TMO261030C00550000) stock price, news, quote and history TMO Oct 2026 550.000 call (TMO261030C00550000) stock price, news, quote and history Yahoo Finance UK
-
TMO Nov 2026 510.000 put (TMO261120P00510000) Stock Historical Prices & Data TMO Nov 2026 510.000 put (TMO261120P00510000) Stock Historical Prices & Data Yahoo! Finance Canada
-
-
-
TMO Oct 2026 730.000 call (TMO261030C00730000) stock price, news, quote and history TMO Oct 2026 730.000 call (TMO261030C00730000) stock price, news, quote and history Yahoo Finance Australia
-
-
Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook Yahoo Finance
-
-
-
-
-
-
-
-
-
TMO Sep 2027 540.000 put (TMO270917P00540000) Stock Price, News, Quote & History TMO Sep 2027 540.000 put (TMO270917P00540000) Stock Price, News, Quote & History Yahoo! Finance Canada
-
-
-
More Health Care stocks
- SOLV Solventum
- STE Steris
- SYK Stryker Corporation
- TECH Bio-Techne
- UHS Universal Health Services
- UNH UnitedHealth Group
- VEEV Veeva Systems
- VRTX Vertex Pharmaceuticals